## Table, Supplemental Digital Content 1: Treatment Adherence Analysis Population Demographics and Clinical Characteristics at Baseline by Cirrhosis Status and Treatment Duration

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Baseline characteristic** | **Patients receiving  8-week treatment** | | **Patients receiving  12-week treatment** | |
| **without cirrhosis  (n=961)** | **with compensated cirrhosis  (n=343)** | **without cirrhosis   (n=673)** | **with compensated cirrhosis  (n=172)** |
| Male | 508 (52.9) | 217 (63.3) | 331 (49.2) | 107 (62.2) |
| Race |  |  |  |  |
| White | 766 (79.7) | 285 (83.1) | 541 (80.5) | 141 (82.0) |
| Black/African American | 67 (7.0) | 28 (8.2) | 22 (3.3) | 12 (7.0) |
| Asian | 112 (11.7) | 28 (8.2) | 96 (14.3) | 15 (8.7) |
| Other  Missing | 16 (1.7)  0 | 2 (0.6)  0 | 13 (1.9)  1 | 4 (2.3)  0 |
| Median (range) age, years | 50 (19–83) | 58 (32–88) | 51 (20–80) | 58 (26–88) |
| BMI ≥30 kg/m2  Missing | 178 (18.5)  1 | 101 (29.4)  0 | 106 (15.8)  0 | 66 (38.4)  0 |
| HCV RNA ≥6,000,000 IU/mL | 248 (25.8) | 53 (15.5) | 134 (19.9) | 19 (11.0) |
| Stable OAT | 84 (8.7) | 27 (7.9) | 53 (7.9) | 19 (11.0) |
| History of injection drug use | 418 (43.5) | 92 (26.8) | 260 (38.6) | 86 (50.0) |
| Current alcohol use | 365 (38.0) | 70 (20.4) | 245 (36.4) | 46 (26.7) |
| Presence of polypharmacy\* | 254 (26.4) | 97 (28.3) | 169 (25.1) | 66 (38.4) |
| History of psychiatric disorder | 278 (28.9) | 71 (20.7) | 190 (28.2) | 67 (39.0) |

* Data are n (%) unless otherwise stated; percentages calculated based on nonmissing values.  
  \*Polypharmacy was defined as ≥5 concomitant medications.  
  BMI, body mass index; HCV, hepatitis C virus; OAT, opioid agonist therapy; RNA, ribonucleic acid.